Boston Scientific Co. (NYSE:BSX) Shares Sold by First Citizens Bank & Trust Co.

First Citizens Bank & Trust Co. trimmed its holdings in Boston Scientific Co. (NYSE:BSX) by 24.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,468 shares of the medical equipment provider’s stock after selling 2,460 shares during the quarter. First Citizens Bank & Trust Co.’s holdings in Boston Scientific were worth $667,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in BSX. Susquehanna Fundamental Investments LLC acquired a new stake in Boston Scientific in the 2nd quarter valued at approximately $2,273,000. Kathmere Capital Management LLC acquired a new stake in Boston Scientific in the 2nd quarter valued at approximately $201,000. Ascent Group LLC increased its position in Boston Scientific by 11.8% in the 2nd quarter. Ascent Group LLC now owns 7,480 shares of the medical equipment provider’s stock valued at $576,000 after acquiring an additional 790 shares during the period. Creative Planning increased its position in Boston Scientific by 13.7% in the 2nd quarter. Creative Planning now owns 189,545 shares of the medical equipment provider’s stock valued at $14,597,000 after acquiring an additional 22,901 shares during the period. Finally, NewEdge Advisors LLC increased its position in Boston Scientific by 34.0% in the 2nd quarter. NewEdge Advisors LLC now owns 81,307 shares of the medical equipment provider’s stock valued at $6,261,000 after acquiring an additional 20,644 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Boston Scientific

In other news, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $90.78, for a total value of $633,916.74. Following the transaction, the executive vice president now directly owns 29,308 shares in the company, valued at approximately $2,660,580.24. The trade was a 19.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Edward J. Ludwig sold 4,877 shares of Boston Scientific stock in a transaction dated Thursday, November 21st. The stock was sold at an average price of $91.63, for a total value of $446,879.51. Following the completion of the transaction, the director now owns 39,398 shares in the company, valued at $3,610,038.74. The trade was a 11.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 29,989 shares of company stock worth $2,702,261 over the last three months. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Price Performance

BSX opened at $102.22 on Tuesday. The stock has a market cap of $150.65 billion, a price-to-earnings ratio of 84.48, a PEG ratio of 2.63 and a beta of 0.80. Boston Scientific Co. has a 1 year low of $60.78 and a 1 year high of $102.32. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44. The stock has a fifty day moving average price of $92.26 and a 200 day moving average price of $85.45.

Analysts Set New Price Targets

BSX has been the topic of several analyst reports. BTIG Research raised their target price on Boston Scientific from $84.00 to $93.00 and gave the company a “buy” rating in a research report on Monday, October 14th. StockNews.com cut Boston Scientific from a “buy” rating to a “hold” rating in a research report on Monday, November 4th. Mizuho lifted their price target on Boston Scientific from $100.00 to $110.00 and gave the company an “outperform” rating in a research report on Thursday, October 24th. Evercore ISI lifted their price target on Boston Scientific from $82.00 to $90.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Finally, Truist Financial lifted their price target on Boston Scientific from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, December 18th. Three investment analysts have rated the stock with a hold rating, twenty have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $97.26.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.